IS6298A - Teridínón sem tálmar kínasa - Google Patents

Teridínón sem tálmar kínasa

Info

Publication number
IS6298A
IS6298A IS6298A IS6298A IS6298A IS 6298 A IS6298 A IS 6298A IS 6298 A IS6298 A IS 6298A IS 6298 A IS6298 A IS 6298A IS 6298 A IS6298 A IS 6298A
Authority
IS
Iceland
Prior art keywords
teridinone
inhibits kinase
kinase
inhibits
Prior art date
Application number
IS6298A
Other languages
English (en)
Inventor
Alexander Denny William
Myra Dobrusin Ellen
Bernard Kramer James
Joseph Mcnamara Dennis
William Rewcastle Gordon
Daniel Hollis Showalter Howard
Laurence Toogood Peter
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS6298A publication Critical patent/IS6298A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
IS6298A 1999-09-15 2002-03-13 Teridínón sem tálmar kínasa IS6298A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15409599P 1999-09-15 1999-09-15
PCT/US2000/017037 WO2001019825A1 (en) 1999-09-15 2000-06-21 Pteridinones as kinase inhibitors

Publications (1)

Publication Number Publication Date
IS6298A true IS6298A (is) 2002-03-13

Family

ID=22549985

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6298A IS6298A (is) 1999-09-15 2002-03-13 Teridínón sem tálmar kínasa

Country Status (29)

Country Link
US (2) US7169778B2 (is)
EP (1) EP1409487A1 (is)
JP (1) JP2003509425A (is)
KR (1) KR20020027649A (is)
CN (1) CN1373763A (is)
AP (1) AP2002002479A0 (is)
AU (1) AU777468B2 (is)
BG (1) BG106594A (is)
BR (1) BR0013952A (is)
CA (1) CA2393896A1 (is)
CR (1) CR6586A (is)
CZ (1) CZ2002846A3 (is)
DZ (1) DZ3186A1 (is)
EA (1) EA005287B1 (is)
EE (1) EE200200140A (is)
HK (1) HK1048992A1 (is)
HU (1) HUP0202713A3 (is)
IL (1) IL148614A0 (is)
IS (1) IS6298A (is)
MA (1) MA26819A1 (is)
MX (1) MXPA02001108A (is)
NO (1) NO20021239L (is)
NZ (1) NZ516872A (is)
OA (1) OA12010A (is)
PL (1) PL353269A1 (is)
SK (1) SK3542002A3 (is)
WO (1) WO2001019825A1 (is)
YU (1) YU18502A (is)
ZA (1) ZA200200896B (is)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6858608B2 (en) * 2001-01-09 2005-02-22 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agents
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
HUP0401711A3 (en) * 2001-06-26 2009-07-28 Bristol Myers Squibb Co N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP1427730B1 (de) * 2001-09-04 2006-07-12 Boehringer Ingelheim Pharma GmbH & Co.KG Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
DE60303009T2 (de) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
DE10212100A1 (de) * 2002-03-11 2003-10-23 Schering Ag CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
EP1542989B1 (en) * 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
EP2039683B1 (en) * 2002-10-03 2012-12-19 Targegen, Inc. Vasculostatic agents and methods of use thereof
AU2003273675A1 (en) * 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
UA80743C2 (en) * 2003-02-26 2007-10-25 Boehringer Ingelheim Pharma Dihydropteridinones, method for the production and use thereof in the form of drugs
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006002367A1 (en) * 2004-06-23 2006-01-05 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
US7423053B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
DE102004034623A1 (de) * 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1828186A1 (en) * 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
AR060432A1 (es) * 2006-04-12 2008-06-18 Vertex Pharma Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas
EP2029599A1 (en) * 2006-05-19 2009-03-04 Astra Zeneca AB Dihydropteridine compounds as anti proliferative agents
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
KR20090057416A (ko) 2006-10-05 2009-06-05 씨브이 쎄러퓨틱스, 인코포레이티드 스테아로일 ＣｏＡ 탈포화효소 억제제로서 사용하기 위한, 바이시클릭 질소 함유 헤테로시클릭 화합물
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP1953163A1 (en) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
EP2131844A1 (en) * 2007-04-09 2009-12-16 CV Therapeutics Inc. PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2185559A1 (en) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
CN103122001A (zh) 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
JP5400791B2 (ja) 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ジヒドロプテリジン−６−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
WO2009137201A1 (en) 2008-04-04 2009-11-12 Cv Therapeutics, Inc. Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2477987B1 (en) 2009-09-14 2018-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
KR20120094920A (ko) 2009-09-25 2012-08-27 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
KR20120096474A (ko) 2009-09-25 2012-08-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8546566B2 (en) * 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
WO2013071217A1 (en) * 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones
CN106008511B (zh) * 2012-05-14 2018-08-14 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2015193228A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターを調製する方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106279173A (zh) * 2015-05-29 2017-01-04 华东理工大学 蝶啶酮衍生物作为egfr抑制剂的应用
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
CN106892922B (zh) * 2015-12-18 2019-04-19 华东理工大学 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
CN107151249B (zh) * 2016-03-04 2020-08-14 华东理工大学 作为flt3抑制剂的蝶啶酮衍生物及应用
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
CN108721298A (zh) * 2017-04-19 2018-11-02 华东理工大学 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用
WO2020033823A1 (en) * 2018-08-10 2020-02-13 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
CN111217815B (zh) * 2018-11-27 2021-06-18 沈阳药科大学 含有喋啶酮骨架的化合物及其制备方法和应用
TWI748317B (zh) * 2019-01-03 2021-12-01 美商建南德克公司 吡啶并－嘧啶酮與喋啶酮化合物及使用方法
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN110357885A (zh) * 2019-07-24 2019-10-22 江南大学 一种蝶啶类化合物及其在药学上的应用
CN113801118A (zh) * 2020-06-12 2021-12-17 华东理工大学 作为rsk抑制剂的蝶啶酮衍生物及其应用
WO2022177302A1 (ko) * 2021-02-17 2022-08-25 보령제약 주식회사 Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
CN113087708A (zh) * 2021-04-06 2021-07-09 南方医科大学 一种蝶啶酮类化合物及其应用
CN115850281A (zh) * 2021-09-24 2023-03-28 华东理工大学 蝶啶酮衍生物及其应用
CN115010711B (zh) * 2022-07-12 2024-12-03 江南大学 一种蝶啶7（8h）-酮类化合物及其在药学上的应用
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53124296A (en) * 1977-04-05 1978-10-30 Mitsubishi Chem Ind Ltd Penicillin derivatives
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JPH1180131A (ja) * 1997-09-01 1999-03-26 Mitsubishi Chem Corp エチニルピリミジン誘導体
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
CR6586A (es) 2004-02-02
DZ3186A1 (fr) 2001-03-22
NO20021239D0 (no) 2002-03-13
EP1409487A1 (en) 2004-04-21
EA005287B1 (ru) 2004-12-30
CN1373763A (zh) 2002-10-09
CA2393896A1 (en) 2001-03-22
ZA200200896B (en) 2003-07-30
NZ516872A (en) 2003-10-31
AP2002002479A0 (en) 2002-06-30
NO20021239L (no) 2002-03-13
US20030130286A1 (en) 2003-07-10
OA12010A (en) 2006-04-19
AU5629500A (en) 2001-04-17
HK1048992A1 (zh) 2003-04-25
MA26819A1 (fr) 2004-12-20
SK3542002A3 (en) 2003-04-01
US7169778B2 (en) 2007-01-30
CZ2002846A3 (cs) 2003-02-12
MXPA02001108A (es) 2002-08-20
KR20020027649A (ko) 2002-04-13
IL148614A0 (en) 2002-09-12
WO2001019825A1 (en) 2001-03-22
JP2003509425A (ja) 2003-03-11
YU18502A (sh) 2004-12-31
EA200200078A1 (ru) 2002-12-26
HUP0202713A3 (en) 2005-02-28
BG106594A (en) 2002-12-29
AU777468B2 (en) 2004-10-21
PL353269A1 (en) 2003-11-03
BR0013952A (pt) 2002-05-14
HUP0202713A2 (hu) 2002-12-28
EE200200140A (et) 2003-04-15
US20070049600A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
IS6298A (is) Teridínón sem tálmar kínasa
IS2165B (is) Týrósín kínasa latar
IS7328A (is) Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum
IS5938A (is) Staðgeng pýrasól sem P38 kínasa tálmar
IS6335A (is) Kínazólín afleiður sem VEGF latar
DE10084662T1 (de) Mehrfachbahn-Verbinden
IL151104A0 (en) Kinase inhibitors
DE60039047D1 (de) Ausfahrbares raumteil
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
EP1262496A4 (en) fluorinated copolymers
DE50100256D1 (de) Polybenzoxazol-vorstufen
DE50113354D1 (de) Klarlackschicht
IS2137B (is) Heteróhringlaga efnasambönd sem tálma æðamyndun
ES1047558Y (es) Colgador
ID26881A (id) Bubutan finer
ATA90082000A (de) Sitzmöbel
AT3550U3 (de) Futterautomat
IT251199Y1 (it) Ecoblocco autoagganciante
DK1226136T3 (da) Tyrosinkinaseinhibitor
SE0000602D0 (sv) Bjälklagselement
UA4415S (uk) Дошка для підлоги
SE9903680D0 (sv) Justeringsanordning
FI5186U1 (fi) Järjestely telan ripustamiseksi
SK2355U (sk) Polosamonosná podlaha
GB0022412D0 (en) Duet